タケウチ　ツトム   TAKEUCHI Tsutomu   竹内　勤    所属   埼玉医科大学  医学部 学長室    職種   学長
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2).
掲載誌名	正式名：Modern Rheumatology 略　 称：MR
掲載区分	国外
出版社	Oxford University Press
著者・共著者	Tanaka Y, Takeuchi T, Morita Y, Kaneko Y, and Terada W.
発行年月	2023/12/07
概要	Objectives This post hoc analysis of the RAJ2 study assessed long-term safety and effectiveness of peficitinib 100 mg/day for treatment of rheumatoid arthritis. Results Overall, no new safety findings were reported at W48, and renal function was unaffected. Of patients included in effectiveness analyses at W48, 70.9% (451/636) had maintained peficitinib 100 mg/day since W0. Of patients who achieved CDAI remission at W0 and maintained peficitinib 100 mg/day to W48, 50.3% (79/157) maintained CDAI remission to W48. Low disease activity and a lower number of prior disease-modifying antirheumatic drugs were significantly associated with CDAI remission at W48. Conclusions Long-term peficitinib treatment at a dose of 100 mg/day was generally well tolerated and, following induction therapy, maintained effectiveness through to W48.